FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy. More Information. June 13, 2018 More Information
FDA approved bevacizumab (Avastin, Genentech, Inc.) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection. More Information. June 13, 2018 More Information
The Food and Drug Administration (FDA) has approved Sodium Oxybate Oral Solution, the first generic version of Jazz’s Xyrem Oral Solution.
The FDA has approved the first generic version of Jazz Pharmaceuticals’ Xyrem (sodium oxybate) oral solution to treat cataplexy and excessive daytime Continue Reading
The newly minted chairman of the influential House Energy & Commerce Committee is looking to tackle Continue Reading